display:none
Skip to main content

New resources! Looking to scale your DHT in global markets? Explore DiMe's new International Regulatory Pathways resources.

Learn more

Work with DiMe on an upcoming project

Learn more

Quantifying the ROI of using digital endpoints

“Collaboration in the development of digital endpoints can spread both cost and risk to further increase absolute value for every organization. If going at it alone returns substantive value, think of the value we can achieve by going at it together.” –Joseph A. DiMasi, Ph.D. Director of Economic Analysis and Research Associate Professor, Tufts Center for the Study of Drug Development

Joseph A. DiMasi, Ph.D., Director of Economic Analysis and Research Associate Professor, Tufts Center for the Study of Drug Development

Tufts Center for the Study of Drug Development (CSDD), Digital Medicine Society (DiMe), and other industry leaders combined forces to take on research that had never been done before: Quantifying the financial costs and benefits associated with using digital endpoints. The results empower decision-makers and digital health innovators with the evidence of substantial value and return on investment (ROI) they need to invest in digital endpoints and advance clinical research.

Key findings

  • Enhanced efficiency: Digital endpoints significantly shorten trial phases and permit smaller trial enrollment sizes
  • Financial gains: Phase 3 trials showed an increase in eNPV between $24M and $40M per indication
  • High ROI: Returns on investment range from 4 to 6 times the cost of implementation

Explore the resources

More DiMe stories

    Join our next project

    Help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients

    Join the Integrated Evidence Plans project

    Join us
    Not today